Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more
Xintela AB (XINT) - Total Liabilities
Latest total liabilities as of September 2025: Skr36.95 Million SEK
Based on the latest financial reports, Xintela AB (XINT) has total liabilities worth Skr36.95 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xintela AB - Total Liabilities Trend (2013–2024)
This chart illustrates how Xintela AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xintela AB Competitors by Total Liabilities
The table below lists competitors of Xintela AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Geohan Corporation Berhad
KLSE:5345
|
Malaysia | RM291.33 Million |
|
Red Light Holland Corp
OTCQB:TRUFF
|
USA | $3.41 Million |
|
NEXTCHIP Co. Ltd
KQ:092600
|
Korea | ₩63.56 Billion |
|
Ornsirin Holding Public
BK:ORN
|
Thailand | ฿2.08 Billion |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
Turkey | TL340.74 Million |
|
Kantone Holdings Limited
PINK:KTHGF
|
USA | $85.46 Million |
|
Excel Force MSC Bhd
KLSE:0065
|
Malaysia | RM16.39 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Xintela AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.09 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xintela AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xintela AB (2013–2024)
The table below shows the annual total liabilities of Xintela AB from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr30.75 Million | +119.39% |
| 2023-12-31 | Skr14.02 Million | -25.21% |
| 2022-12-31 | Skr18.74 Million | -9.88% |
| 2021-12-31 | Skr20.80 Million | -0.53% |
| 2020-12-31 | Skr20.91 Million | +169.10% |
| 2019-12-31 | Skr7.77 Million | +62.91% |
| 2018-12-31 | Skr4.77 Million | -53.11% |
| 2017-12-31 | Skr10.17 Million | +254.85% |
| 2016-12-31 | Skr2.87 Million | -9.33% |
| 2015-12-31 | Skr3.16 Million | +231.24% |
| 2014-12-31 | Skr954.29K | -52.34% |
| 2013-12-31 | Skr2.00 Million | -- |